Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

TSX:VRX - Post Discussion

VALEANT PHARMACEUTICALS INTL INC > Lot of negative articles
View:
Post by justacomment on Jul 18, 2016 1:23pm

Lot of negative articles

Not a conspiracy theorist but seems that every story on VRX has a negative spin to it.  Even if the drug review is successful, there seems to be a lot of articles lined up on bashing the revenue stream.

It takes a lot of effort to turn sentiment and it don'ts seem to be going that way for VRX.
Comment by knowsnothing on Jul 18, 2016 8:02pm
Those with negative articles have or related to whom have ahort positions... let's see what happens in the next few days
Comment by richc3 on Jul 18, 2016 10:28pm
Tomorrow will certainly be a big day for us, but some of it may come down to timing. Relistor is expected to be approved and should give us a good shot in the arm, but the FDA meeting to discuss brodalumab, which is also on Tuesday, will likely lean towards the more negative side of things. So a big question is, what time will the results be released on each of these tomorrow and how will the ...more  
Comment by acelliste on Jul 18, 2016 11:52pm
Even If brodalumab is negative, an approval of relistor oral should be huge positve for the stock.  For comparison, if the Walgreen conference call comment raised VRX a few dollars imagine how high the share price will be with a new drug approval. But then again the market is nuts.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities